Pamela Esposito sold $2.3M of KYMR
director at Kymera Therapeutics, Inc.. 27,563 shares at an average of $82.16, traded Dec 17, 2025, filed Dec 17, 2025.
Score components
- +15RoleDirector
- +25Trade size$2.3M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -15.3%, 3m -3.6%, 6m +9.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-323090, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 17, 2025 | MOption exercise Common Stock10b5-1 | +12,563 | $49.10 | $617k | 12,563 | Dec 17, 2025 |
| Dec 17, 2025 | MOption exercise Common Stock10b5-1 | +12,000 | $27.67 | $332k | 24,563 | Dec 17, 2025 |
| Dec 17, 2025 | MOption exercise Common Stock10b5-1 | +3,000 | $31.20 | $94k | 27,563 | Dec 17, 2025 |
| Dec 17, 2025 | SOpen-market sale Common Stock10b5-1 | -14,505 | $81.56 | $1.2M | 13,058 | Dec 17, 2025 |
| Dec 17, 2025 | SOpen-market sale Common Stock10b5-1 | -7,959 | $82.34 | $655k | 5,099 | Dec 17, 2025 |
| Dec 17, 2025 | SOpen-market sale Common Stock10b5-1 | -4,099 | $83.45 | $342k | 1,000 | Dec 17, 2025 |
| Dec 17, 2025 | SOpen-market sale Common Stock10b5-1 | -1,000 | $84.07 | $84k | 0 | Dec 17, 2025 |
| Dec 17, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,563 | $0.00 | $0 | 7,500 | Dec 17, 2025 |
| Dec 17, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,000 | $0.00 | $0 | 0 | Dec 17, 2025 |
| Dec 17, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,000 | $0.00 | $0 | 13,000 | Dec 17, 2025 |
Related signals
Other insiders at Kymera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $3.4M 30,000 shares | -4% | |
| 41Moderate | KYMRsell Kymera Therapeutics, Inc. | Brian Adams Chief Legal Officer | $744k 6,371 shares | -11% | |
| 30Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $6.0M 50,000 shares | -7% | |
| 26Weak | Kymera Therapeutics, Inc. | Noah Goodman Chief Business Officer | $387k 3,389 shares | -7% | |
| 32Weak | Kymera Therapeutics, Inc. | Bruce N. Jacobs Chief Financial Officer | $8.9M 77,109 shares | -24% | |
| 35Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $9.2M 80,000 shares | -11% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $8.3M 76,650 shares | -3% | |
| 40Moderate | Kymera Therapeutics, Inc. | Bruce Booth director | $56M 513,245 shares | -18% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $3.4M 31,283 shares | -1% | |
| 75Notable | Kymera Therapeutics, Inc. | Bvf Partners L P/il director, other | $174M 1,630,658 shares | -58% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.